Retatrutide Drug Information

  • Retatrutide drug information
  • Learn about retatrutide medication

Retatrutide - Overview

Retatrutide is a drug that is under investigated for weight loss. Retatrutide is not approved by the FDA and is not available in the US market at this time.

What Is Retatrutide Used For?

Retatrutide, sometimes referred to as LY3437943, is an investigational drug. Retatrutide belongs to a new class of medications that combine glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 (GLP-1) and glucagon.

Retatrutide And Weight Loss

Retatrutide is under investigation for use in weight loss. In one phase 2 trial, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. Retatrutide will likely be a once-weekly injection and is similar to drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro). Retatrutide targets GLP-1 receptors and two other hormones known as glucagon and glucose-dependent insulinotropic polypeptide (GIP). Due to these actions, retatrutide is sometimes referred to as a "triple G" (GGG) or tri-agonist drug.

Retatrutide - Side Effects

Retatrutide can cause side effects when used but, to date, is generally well tolerated. Retatrutide may cause adverse reactions such as an increased heart rate and tingling of the skin.

More Retatrutide Information

Last updated August 30, 2023. Given the evolving nature of medicine and science, this information might not be accurate and should not be construed as medical advice or diagnosis / treatment recommendations. Please consult a licensed medical provider if you have additional questions. Please call 911 immediately or go to the nearest emergency room if you believe you are experiencing a medical emergency.